OCULAR THERAPEUTIX, INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Ocular Therapeutix's (OCUL) CDO Peter Kaiser sold 9,990 shares for $70,429 on Oct 2, 2026, at an average price of $7.05. The sale was automatic to cover tax obligations. OCUL shares are down 40% YTD, trading near a 52-week low. Analysts see potential, with targets up to $34. The company is progressing with FDA meetings for its wAMD drug candidate.
Ocular Therapeutix Inc (OCUL) shares fell 5% on Thursday, on track for their worst week since April 2024, after rivals Kodiak Sciences and 4D Molecular Therapeutics posted positive updates in the wet AMD market. OCUL's lead drug, AXPAXLI, remains on track for FDA filing in Q4 2026. Analysts see potential but shares have dropped 40% YTD.
Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning OCUL (OCULAR THERAPEUTIX, INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent OCUL coverage spans financial news, market movers and regulation.
In the last 30 days, OCUL insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($147K). The most active reporter was Kaiser Peter, Chief Development Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale suggests modest downside pressure on OCUL as a key executive reduces his stake.
The stock is under pressure as investors shift focus to competitors with more promising durability data.
Sharp sell‑off likely to continue as market doubts efficacy gap.
Significant price drop driven by sector‑wide regulatory news.
The FDA meeting clears a major regulatory hurdle, positioning OCUL for a potential approval-driven rally.
AlphAI scores every news story that mentions OCUL with an AI model for sentiment and relevance, and aggregates insider trades from OCULAR THERAPEUTIX, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocular Therapeutix's (OCUL) CDO Peter Kaiser sold 9,990 shares for $70,429 on Oct 2, 2026, at an average price of $7.05. The sale was automatic to cover tax obligations. OCUL shares are down 40% YTD, trading near a 52-week low. Analysts see potential, with targets up to $34. The company is progressing with FDA meetings for its wAMD drug candidate.
1 min readOcular Therapeutix Inc (OCUL) shares fell 5% on Thursday, on track for their worst week since April 2024, after rivals Kodiak Sciences and 4D Molecular Therapeutics posted positive updates in the wet AMD market. OCUL's lead drug, AXPAXLI, remains on track for FDA filing in Q4 2026. Analysts see potential but shares have dropped 40% YTD.
2 min readOcular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
2 min readOcular Therapeutix (OCUL) and ANI Pharmaceuticals (ANIP) stocks fell 6.7% and 4.3%, respectively, as healthcare sector sentiment weakened due to CMS canceling Affordable Care Act coverage for 760,000 people and clawing back $2.2B in subsidies. OCUL is down 13.8% YTD and 36.7% from its 52-week high.
2 min readOcular Therapeutix (OCUL) announced a positive Pre-NDA meeting with the FDA for AXPAXLI, its treatment for wet age-related macular degeneration. The NDA is on track for submission in Q4 2026. AXPAXLI showed significant efficacy in clinical trials, with 74.1% of patients maintaining vision at Week 36, and up to 72% fewer injections compared to aflibercept. The company aims to leverage existing safety data to expedite the review process.
2 min readOcular Therapeutix (OCUL) completed a Pre-NDA meeting with the FDA for AXPAXLI, its wet AMD treatment. The meeting confirmed the NDA submission plan for Q4 2026, supported by Phase 3 trial data. AXPAXLI is also in trials for diabetic retinal disease. OCUL stock is up 2.19% to $10.72.
2 min readOcular Therapeutix (OCUL) reported Q2 2026 results, highlighting AXPAXLI's progress for wet age-related macular degeneration. The FDA confirmed the NDA filing timeline, with potential for a faster review. Costs rose, with R&D at $54.1M, marketing at $17.3M, and net loss widening to $78.8M. Cash reserves decreased to $598.6M. AXPAXLI's data suggests fewer patient injections, and early market research shows high adoption potential. Institutional interest grew, but short interest remains high.
3 min readOcular Therapeutix (OCUL) has a notice of proposed sale of 1,099 shares of common stock by Donald D. Notman Jr. The shares, valued at $11,251.89, are restricted stock vesting under a registered plan and will be sold through Morgan Stanley Smith Barney LLC. The transaction is set for August 31, 2026, with the stock vesting on August 29, 2026.
1 min readOcular Therapeutix's Executive Chairman, Pravin Dugel, sold $233k worth of shares at $10.77 each, following a larger sale earlier this year. Insiders have sold more shares than they bought in the past year, with total insider ownership at 1.2% of the company. The insider activity does not strongly indicate confidence in the stock's value.
2 min readOcular Therapeutix (OCUL) CEO Pravin Dugel sold 21,649 shares at $10.77 each to cover tax obligations, retaining 2,525,429 shares. His spouse transferred 50,092 shares to a trust. OCUL is down 11% YTD but up 12% in 6 months. Analysts set price targets between $18 and $34. The company plans to submit an NDA for AXPAXLI in Q4 2026, with H.C. Wainwright raising its target to $25 and Citizens to $34.
2 min read
